Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
VANCOUVER, British Columbia, Jan. 12, 2016 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) (“QLT” or the “Company”) is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company’s annual general meeting held on January 8, 2016 (the “Meeting”).
Detailed results of the vote for the election of directors are as follows:
| Nominee | Votes For | % | Votes Withheld | % |
| Jason M. Aryeh | 30,993,845 | 90.32 | 3,321,352 | 9.68 |
| Dr. Geoffrey F. Cox, Ph.D | 31,208,904 | 90.95 | 3,106,293 | 9.05 |
| Dr. John W. Kozarich, Ph.D | 31,223,945 | 90.99 | 3,091,252 | 9.01 |
| Jeffrey A. Meckler | 30,811,599 | 89.79 | 3,503,598 | 10.21 |
| Dr. Stephen L. Sabba, M.D. | 31,202,781 | 90.93 | 3,112,416 | 9.07 |
| John C. Thomas, Jr. | 30,971,911 | 90.26 | 3,343,286 | 9.74 |
Final voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.sec.gov.
About QLT
QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases.
QLT’s head office is based in Vancouver, Canada and the Company is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT). For more information about the Company’s products and developments, please visit our web site at www.qltinc.com.
QLT Inc. Contacts: For Investors: Andrea Rabney or David Pitts Argot Partners P: 212-600-1902 [email protected] [email protected]
